Adjuvant endocrine therapy in postmenopausal breast cancer patients

Breast

Volumn 14, Issue 6, 2005, Pages 446-451

  Köberle, Dieter ^a   Thürlimann, Beat ^a  

^a CANTONAL HOSPITAL ST GALLEN   (Switzerland)

Author keywords

Aromatase inhibitors; Oestrogen receptor positive breast cancer; Tamoxifen

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; CELECOXIB; ESTROGEN RECEPTOR; EXEMESTANE; LETROZOLE; PLACEBO; TAMOXIFEN;

ARTHRALGIA; ARTHRITIS; BRAIN ISCHEMIA; BREAST CANCER; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DEATH; DRUG FATALITY; ENDOMETRIUM CANCER; FOLLOW UP; FRACTURE; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; LYMPH NODE METASTASIS; METASTASIS POTENTIAL; MYALGIA; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; VAGINA BLEEDING; VAGINA DISCHARGE; VENOUS THROMBOEMBOLISM;

EID: 28044464912     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2005.08.003     Document Type: Article

References (13)

1. Early breast cancer Trialists' Collaborative Group Effects of chemotherapy and hormonal therapy on recurrence and 15-year survival: An overview of the randomised trials Lancet 365 2005 1687-1717
2. H.T. Mouridsen Aromatase inhibitors in advanced breast cancer Semin Oncol 31 Suppl 12 2004 3-8
3. I.E. Smith M. Dowsett Aromatase inhibitors in breast cancer N Engl J Med 384 2003 2432-2442
4. M. Baum A.U. Buzdar J. Cuzick for the ATAC Trialists' Group et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial Lancet 359 2002 2131-2139
5. A. Howell J. Cuzick M. Baum et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer Lancet 365 2005 60-62
6. Thürlimann B.J., Keshaviah A., Mouridsen H., et al. BIG 1-98: Randomized double-blind phase III study to evaluate letrozole vs. tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. Proc ASCO 2005 [abstract 511].
7. R.C. Coombes E. Hall L.J. Gibson et al. A randomized trial of exemestane after two to three years of tamoxifen in postmenopausal women with primary breast cancer N Engl J Med 350 2004 1081-1092
8. R. Jakesz W. Jonat M. Gnant et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: Combined results of ABCSG trial 8 and ARNO 95 trial Lancet 366 2005 455-462
9. F. Boccardo A. Rubagotti D. Amoroso et al. Anastrozole appears to be superior to tamoxifen in women already receiving adjuvant tamoxifen treatment Breast Cancer Res Treat 82 2003 [abstr. 3]
10. P.E. Goss J. Ingle S. Martino et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early stage breast cancer N Engl J Med 349 2003 1793-1802
11. P.E. Goss J. Ingle S. Martino et al. Updated analysis of the NCIC CTG MA.17 randomized placebo (P) controlled trial of letrozole (L) after five years of tamoxifen in postmenopausal women with early stage breast cancer American Society of Clinical Oncology annual meeting 23 2004 [abstr. 847]
12. E.P. Winer C. Hudis H.J. Burstein et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: Status report 2004 J Clin Oncol 23 2005 619-629
13. R.C. Coombes E. Hall C.F. Snowdon et al. The Intergroup Exemestane Study: A randomized trial in postmenopausal patients with early breast cancer who remain disease-free after two or three years of tamoxifen-updated survival analysis Breast Cancer Res Treat 88 Suppl 1 2004 S7